Abstract
BackgroundResistance to chemotherapy is a major obstacle in the effective treatment of cancer patients. B7-homolog 1, also known as programmed death ligand-1 (PD-L1), is an immunoregulatory protein that is overexpressed...
Highlights
Resistance to chemotherapy is a major obstacle in the effective treatment of cancer patients
B7-homolog 1 (B7-H1) protein is detectable by immunohistochemistry in esophageal adenocarcinoma biopsies We have shown that B7-H1 expression can be induced in a 5-FU dose dependent manner in OE33 cells
We have demonstrated that while B7-H1 expression is low at baseline its expression can be induced in HCT 116 p53+/+, HCT 116 p53−/− and OE33 cells following treatment with 5-FU, the chemotherapy of choice for both advanced colorectal cancer (CRC) and esophageal adenocarcinoma (EAC)
Summary
Resistance to chemotherapy is a major obstacle in the effective treatment of cancer patients. B7-homolog 1, known as programmed death ligand-1 (PD-L1), is an immunoregulatory protein that is overexpressed in several human cancers. Methods: HCT 116 p53+/+, HCT 116 p53−/− colorectal cancer (CRC) and OE33 esophageal adenocarcinoma (EAC) cells were treated with increasing doses of 5-FU (0.5 uM, 5 uM, 50 uM, 500 uM) or interferon gamma (IFN-γ, 10 ng/ mL) in culture for 24 h and B7-H1 expression was quantified using flow cytometry and western blot analysis. Results: B7-H1 expression in human HCT 116 p53+/+ and HCT 116 p53−/− CRC cells lines, while low at baseline, can be induced by treatment with 5-FU. OE33 baseline B7-H1 expression exceeded CRC cell maximal expression and could be further increased in a dose dependent manner following 5-FU treatment in the absence of immune cells. While B7-H1 expression was not enhanced in post-treatment esophagectomy specimens, this may be due to the limits of immunohistochemical quantification
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
